arrow
Y

Yannick Le Bris

Nantes Universite
H指数:20
被引数:1,158

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival

CD40/PI3K/FOXO1轴的重编程驱动微环境依赖性的BIM沉默,以维持淋巴瘤的生长和存活。

Leukemia
IF13.4
2026-02-190
PRE
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

阿扎胞苷治疗VEXAS综合征的疗效与安全性:FRENVEX小组的一项大规模回顾性研究

Blood
IF23.1
2025-05-190
PRE
Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

p16的异常细胞质表达是接受一线阿糖胞苷为基础的免疫化疗的年轻MCL患者的一个新的强预后标志物,一项来自Lysa Group、Nordic Lymphoma Group和European MCL Network的研究

BLOOD
IF23.1
2024-11-050
PRE
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloproliferatifs
2024-02-084
OAAI
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
2024-01-022
PRE
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia

FLT3基因中的非常短的插入在急性髓性白血病中具有治疗意义

2023-12-151
OAAI
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
2023-07-0111
PRE
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome
2021-10-0130
OAAI
Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
2021-03-0551
OA
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft
2020-09-212
OAAI
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by theLYSAgroup
2020-06-257
PREAI